Journal of Clinical Immunology

, Volume 16, Issue 6, pp 334–339 | Cite as

Natural killing activity in patients with spontaneous regression of malignant lymphoma

  • Kazutoshi Ono
  • Masako Kikuchi
  • Noriko Funai
  • Miwako Matsuzaki
  • Yoshinori Shimamoto
Original Articles


Previously, we proposed a new analysis of natural killing activity, for comparison, employing an “individual effector/ target cell ratio” according to the number of effector cells in blood. The activity could be measured in four patients with spontaneous regression of malignant lymphoma. Despite the absence of episodes suggesting viral infections, patients with spontaneous regression had significantly higher activities prior to their regressions than either controls or patients without regression. In one patient who had a spontaneous regression accompanied by a high level of natural killing activity, subsequent exacerbation of the disease with a reduced activity was never followed by a regression and became life-threatening. In another patient, a spontaneous regression was accelerated after greater augmentation of natural killing activity was induced by a superimposed viral infection. These facts suggest that highly elevated natural killing activity may be one of the possible mechanisms responsible for spontaneous regression of malignant lymphoma.

Key words

Natural killing activity spontaneous regression malignant lymphoma non-Hodgkin's lymphoma adult T-cell leukemia/lymphoma 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Gattiker HH, Wiltshaw E, Galton DAG: Spontaneous regression in non-Hodgkin's lymphoma. Cancer 45:2627–2632, 1980PubMedGoogle Scholar
  2. 2.
    Krikorian JG, Portlock CS, Cooney DP, Rosenberg SA: Spontaneous regression of non-Hodgkin's lymphoma: A report of nine cases. Cancer 46:2093–2099, 1980PubMedGoogle Scholar
  3. 3.
    Wiernik PH: Spontaneous regression of hematologic cancers. Natl Cancer Inst Monogr 44:35–38, 1976PubMedGoogle Scholar
  4. 4.
    Horning SJ, Rosenberg SA: The natural history of initially untreated low-grade non-Hodgkin's lymphoma. N Engl J Med 311:1471–1475, 1984PubMedGoogle Scholar
  5. 5.
    Grem JL, Hafez GR, Brandenburg JH, Carbone PP: Spontaneous remission in diffuse large cell lymphoma. Cancer 57:2042–2044, 1986PubMedGoogle Scholar
  6. 6.
    Strauchen JA, Moran C, Goldsmith M, Greenberg M: Spontaneous regression of gastric lymphoma. Cancer 60:1872–1875, 1987PubMedGoogle Scholar
  7. 7.
    Shigematsu A, Iida M, Lien GS, Imamura T, Okada M, Fuchigami T, Fujishima M, Itoh H, Iwashita A: Spontaneous regression of primary malignant lymphoma of the stomach in two nontreated Japanese. J Clin Gastroenterol 11:511–517, 1989PubMedGoogle Scholar
  8. 8.
    Ziegler JL: Spontaneous remission in Burkitt's lymphoma. Natl Cancer Inst Monogr 44:61–65, 1976PubMedGoogle Scholar
  9. 9.
    Poppema S, Postma L, Brinker M, Jong B: Spontaneous regression of a small non-cleaved cell malignant lymphoma (non-Burkitt's lymphoblastic lymphoma): Morphologic, immunohistochemical, and immunoglobulin gene analysis. Cancer 62:791–794, 1988PubMedGoogle Scholar
  10. 10.
    Kimura I, Tsubota T, Hayashi K, Ohnoshi T: Spontaneous complete remission in adult T-cell leukemia: A case report. Jpn J Clin Oncol 13 (Suppl 2):231–236, 1983PubMedGoogle Scholar
  11. 11.
    Schnitzer B, Lovett EJ III, Kahn LE: Adult T-cell leukemia with spontaneous remission. Lancet 2:1030, 1983 (letter)Google Scholar
  12. 12.
    Kawano F, Tsuda H, Yamaguchi K, Nishimura H, Sanada I, Matsuzaki K: Unusual clinical courses of adult T-cell leukemia in siblings. Cancer 54:131–134, 1984PubMedGoogle Scholar
  13. 13.
    Tagawa S, Konoshi I, Tokumine Y, Kuratsune H, Machii T, Kitani T: Phenotypical heterogeneity of Japanese adult T-cell leukemia. Scand J Haematol 32:306–312, 1984PubMedGoogle Scholar
  14. 14.
    Mattock C, Anderson NA, Sheldon CD, Rustin MH, Hoffbrand BI: Spontaneous remission and relapse in adult T-cell lymphoma/leukemia associated with HTLV-I. Br Med J 292:1171–1172, 1986 (letter)Google Scholar
  15. 15.
    Weintraub LR: Lymphosarcoma: Remission associated with viral hepatitis. JAMA 210:1590–1591, 1969PubMedGoogle Scholar
  16. 16.
    Zygiert Z: Hodgkin's disease: Remissions after measles. Lancet 1:953, 1971 (letter)Google Scholar
  17. 17.
    Bluming AZ, Ziegler JL: Regression of Burkitt's lymphoma in association with measles infection. Lancet 2:105–106, 1971 (letter)PubMedGoogle Scholar
  18. 18.
    Taqi AM, Abdurrahman MB, Yakubu AM, Fleming AF: Regression of Hodgkin's disease after measles. Lancet 1:1112, 1981 (letter)Google Scholar
  19. 19.
    McClain K, Warkentin P, Kay N: Spontaneous remission of Burkitt's lymphoma associated with herpes zoster infection. Am J Pediatr Hematol Oncol 7:9–14, 1985PubMedGoogle Scholar
  20. 20.
    Ono K, Shimamoto Y, Nishimura J, Yamaguchi M, Nawata H: A new analysis of natural killing activity and the role of monocytes in normal subjects. J Clin Lab Immunol 30:175–181, 1989PubMedGoogle Scholar
  21. 21.
    Bancroft GJ, Shellam GR, Chalmer JE: Genetic influences on the augmentation of natural killer (NK) cells during murine cytomegalovirus infection: Correlation with patterns of resistance. J Immunol 126:988–994, 1981PubMedGoogle Scholar
  22. 22.
    Ennis FA, Meager A, Beare AS, Hua Q, Riley D, Schwarz Z, Schild GC, Rook AH: Interferon induction and increased natural killer-cell activity in influenza infections in man. Lancet 2:891–893, 1981PubMedGoogle Scholar
  23. 23.
    Rygaard J, Povlsen CO: The mouse mutant nude does not develop spontaneous tumors—an argument against immunological surveillance. Acta Pathol Microbiol Scand B82:99–106, 1974Google Scholar
  24. 24.
    Gorelik E, Wiltrout RH, Okumura K, Habu S, Herberman RB: Role of NK cells in the control of metastatic spread and growth of tumor cells in mice. Int J Cancer 30:107–112, 1982PubMedGoogle Scholar
  25. 25.
    Barlozzari T, Leonhart J, Wiltrout RH, Herberman RB, Reynolds CW: Direct evidence for the role of LGL in the inhibition of experimental tumor metastasis. J Immunol 134:2783–2789, 1985PubMedGoogle Scholar
  26. 26.
    Pross HF, Baines MG, Rubin P, Shragge P, Patterson MS: Spontaneous human lymphocyte-mediated cytotoxicity against tumor target cells. IX. The quantitation of natural killer cell activity. J Clin Immunol 1:51–63, 1981PubMedGoogle Scholar
  27. 27.
    The Non-Hodgkin's Lymphoma Pathologic Classification Project: National Cancer Institute sponsored study of classification of non-Hodgkin's lymphoma: Summary and description of a working formulation for clinical usage. Cancer 49:2112–2135, 1982Google Scholar
  28. 28.
    Gupta S, Fernandes G: Spontaneous and antibody-dependent cellular cytotoxicity by lymphocyte subpopulations in peripheral blood and spleen from adult untreated patients with Hodgkin's disease. Clin Exp Immunol 45:205–214, 1981PubMedGoogle Scholar
  29. 29.
    Tursz T, Dokhelar MC, Lipinski M, Amiel JL: Low natural killer cell activity in patients with malignant lymphoma. Cancer 50:2333–2335, 1982PubMedGoogle Scholar
  30. 30.
    Hawrylowicz CM, Rees RC, Hancock BW, Potter CW: Depressed spontaneous natural killing and interferon augmentation in patients with malignant lymphoma. Eur J Cancer Clin Oncol 18:1081–1088, 1982PubMedGoogle Scholar
  31. 31.
    Levy S, Tempe JL, Aleksijevic A, Giron C, Oberling F, Mayer S, Lang LM: Depressed NK cell activity of peripheral blood mononuclear cells in untreated Hodgkin's disease: Enhancing effect of interferon in vitro. Scand J Haematol 33:386–390, 1984PubMedGoogle Scholar
  32. 32.
    Frydecka I: Natural killer cell activity during the course of disease in patients with Hodgkin's disease. Cancer 56:2799–2803, 1985PubMedGoogle Scholar
  33. 33.
    Mehta B, Advani S, Nadkarni J: Non-Hodgkin's Lymphoma: Natural cell-mediated cytotoxicity correlated with histological classification and prognosis. Oncology 46:323–325, 1989PubMedGoogle Scholar
  34. 34.
    Rajaram N, Tatake RJ, Advani SH, Gangal SG: Natural killer and lymphokine activated killer cell functions in Hodgkin's disease. Br J Cancer 62:205–208, 1990PubMedGoogle Scholar
  35. 35.
    Caldera LH, Leon-Ponte M, Acquatella G, Bianco NE, Bianca I: Bone marrow and peripheral blood natural killer cell activity in lymphomas. Its response to IL-2. Clin Exp Immunol 88:143–148, 1992PubMedGoogle Scholar
  36. 36.
    Ono K, Imazono Y, Misawa T, Nishimura J, Nawata H: Natural killing activity is associated with progression of gastic cancer. J Clin Immunol 15:210–214, 1995PubMedGoogle Scholar
  37. 37.
    Ono K, Yamanaga Y, Yamamoto K, Koga S, Nishimura J, Nawata H: Natural killing activities in chronic liver diseases and hepatocellular carcinoma. J Clin Immunol 16:41–45, 1996PubMedGoogle Scholar
  38. 38.
    Ljunggren HG, Karre K: Experimental strategies and interpretations in the analysis of changes in MHC gene expression during tumour progression. Opposing influences of T cell and natural killer mediated resistance? J Immunogenet 13:141–151, 1986PubMedGoogle Scholar
  39. 39.
    Correa I, Corral L, Raulet DH: Multiple natural killer cellactivating signals are inhibited by major histocompatibility complex class I expression in target cells. Eur J Immunol 24:1323–1331, 1994PubMedGoogle Scholar
  40. 40.
    Trinchieri G: Recognition of major histocompatibility complex class I antigens by natural killer cells. J Exp Med 180:417–421, 1994PubMedGoogle Scholar
  41. 41.
    Oshimi K, Oshimi Y, Yamada O, Mizoguchi H: Lysis of lymphoma cells by autologous and allogenic natural killer cells. Blood 65:638–643, 1985PubMedGoogle Scholar

Copyright information

© Plenum Publishing Corporation 1996

Authors and Affiliations

  • Kazutoshi Ono
    • 1
  • Masako Kikuchi
    • 1
  • Noriko Funai
    • 1
  • Miwako Matsuzaki
    • 1
  • Yoshinori Shimamoto
    • 1
  1. 1.Department of Internal MedicineSaga Medical SchoolSagaJapan

Personalised recommendations